{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:43:08Z","timestamp":1788493388808,"version":"build-2803163510"},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2106,7,5]]},"DOI":"10.18632\/oncotarget.9351","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T20:32:08Z","timestamp":1463171528000},"page":"41017-41030","source":"Crossref","is-referenced-by-count":6,"title":["<i>NRAS<\/i> and <i>EPHB6<\/i> mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand"],"prefix":"10.18632","volume":"7","author":[{"given":"Angela M.","family":"Jones","sequence":"first","affiliation":[{"name":"Capital and Coast District Health Board, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Capital and Coast District Health Board, Wellington, New Zealand"},{"name":"Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqui","family":"Gardner","sequence":"additional","affiliation":[{"name":"Anatomical and Molecular Pathology, Canterbury Health Laboratories, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Rooker","sequence":"additional","affiliation":[{"name":"Capital and Coast District Health Board, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sutton","sequence":"additional","affiliation":[{"name":"Pathlab Bay of Plenty, Tauranga, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand"},{"name":"Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne M.","family":"Bickley","sequence":"additional","affiliation":[{"name":"Anatomical and Molecular Pathology, Canterbury Health Laboratories, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhdoom","family":"Sarwar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Emanuel","sequence":"additional","affiliation":[{"name":"Anatomic Pathology Services, Auckland District Health Board, New Zealand"},{"name":"Department of Pathology and Molecular medicine, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Kenwright","sequence":"additional","affiliation":[{"name":"Capital and Coast District Health Board, Wellington, New Zealand"},{"name":"Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand"},{"name":"Department of Pathology and Molecular medicine, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Eccles","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand"},{"name":"Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","article-title":"The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031","volume":"136","author":"Olsen","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.sder.2011.08.003","article-title":"Ultraviolet radiation and melanoma","volume":"30","author":"Gerstenblith","year":"2011","journal-title":"Seminars in Cutaneous Medicine and Surgery"},{"key":"3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1755-148X.2011.00880.x","article-title":"The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin","volume":"24","author":"Bastian","year":"2011","journal-title":"Pigment Cell & Melanoma Research"},{"key":"4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"485","author":"Ren","year":"2012","journal-title":"Nature"},{"key":"5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Lawrence","year":"2012","journal-title":"Cell"},{"key":"6","doi-asserted-by":"crossref","first-page":"e18257","DOI":"10.1371\/journal.pone.0018257","article-title":"A melanoma molecular disease model","volume":"6","author":"Shrager","year":"2011","journal-title":"PloS One"},{"key":"7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pcmr.12459","article-title":"The genomic landscape of cutaneous melanoma","volume":"29","author":"Hayward","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Balu","year":"2015","journal-title":"Cell"},{"key":"9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.191999.112","article-title":"Melanoma: from mutations to medicine","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes & Development"},{"key":"10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.ejca.2012.11.004","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","volume":"49","author":"Long","year":"2013","journal-title":"European Journal of Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"Maio","year":"2014","journal-title":"The Lancet Oncology"},{"key":"12","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11640870-000000000-00000","article-title":"Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies","volume":"72","author":"Dowell","year":"2012","journal-title":"Drugs"},{"key":"13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-015-0330-z","article-title":"Treatment of NRAS-mutant melanoma","volume":"16","author":"Puzanov","year":"2015","journal-title":"Current Treatment Options in Oncology"},{"key":"14","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.28306","article-title":"Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma","volume":"119","author":"Davies","year":"2013","journal-title":"Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Long","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1535-7163.MCT-11-0676","article-title":"A high-throughput panel for identifying clinically relevant mutation profiles in melanoma","volume":"11","author":"Mann","year":"2012","journal-title":"Molecular Cancer Therapeutics"},{"key":"17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1755-148X.2011.00873.x","article-title":"Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma","volume":"24","author":"McArthur","year":"2011","journal-title":"Pigment Cell & Melanoma Research"},{"key":"18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Lundeberg","year":"2006","journal-title":"Melanoma research"},{"key":"19","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Davies","year":"2012","journal-title":"Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ijc.10978","article-title":"A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?","volume":"104","author":"Smalley","year":"2003","journal-title":"International Journal of Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.1038\/srep07857","article-title":"Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma","volume":"5","author":"Filipp","year":"2015","journal-title":"Scientific Reports"},{"key":"22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma","volume":"15","author":"Luthra","year":"2013","journal-title":"The Journal of Molecular Diagnostics"},{"key":"23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Bauer","year":"2010","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.438","article-title":"Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4","volume":"41","author":"Samuels","year":"2009","journal-title":"Nature Genetics"},{"key":"25","doi-asserted-by":"crossref","first-page":"e44591","DOI":"10.1371\/journal.pone.0044591","article-title":"Mutations of the EPHB6 receptor tyrosine kinase induce a pro-metastatic phenotype in non-small cell lung cancer","volume":"7","author":"Muller-Tidow","year":"2012","journal-title":"PloS One"},{"key":"26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1479-5876-11-202","article-title":"Heterogeneous distribution of BRAF\/NRAS mutations among Italian patients with advanced melanoma","volume":"11","author":"Palmieri","year":"2013","journal-title":"Journal of Translational Medicine"},{"key":"27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1039\/b510943d","article-title":"Geographical differences in erythemally-weighted UV measured at mid-latitude USDA sites","volume":"5","author":"Lantz","year":"2006","journal-title":"Photochemical & Photobiological Sciences"},{"key":"28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/359135a0","article-title":"Increased Ultraviolet-Radiation in New-Zealand (45-Degrees-S) Relative to Germany (48-Degrees-N)","volume":"359","author":"Mckenzie","year":"1992","journal-title":"Nature"},{"key":"29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Dutton-Regester","year":"2012","journal-title":"Nature Genetics"},{"key":"30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/labinvest.2013.84","article-title":"Melanoma genotypes and phenotypes get personal","volume":"93","author":"Nickoloff","year":"2013","journal-title":"Laboratory Investigation"},{"key":"31","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1186\/1471-2458-14-1001","article-title":"Vitamin D levels in an Australian population","volume":"14","author":"Adams","year":"2014","journal-title":"BMC Public Health"},{"key":"32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jsbmb.2013.01.011","article-title":"Vitamin D status: multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient","volume":"136","author":"Dwyer","year":"2013","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"33","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/1753-6405.12390","article-title":"Incidence and characteristics of vitamin D deficiency rickets in New Zealand children: a New Zealand Paediatric Surveillance Unit study","volume":"39","author":"Taylor","year":"2015","journal-title":"Australian and New Zealand journal of Public Health"},{"key":"34","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1039\/c2pp25202c","article-title":"1 alpha,25 Dihydroxyvitamin D-3 enhances cellular defences against UV-induced oxidative and other forms of DNA damage in skin","volume":"11","author":"Mason","year":"2012","journal-title":"Photoch Photobio Sci"},{"key":"35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jsbmb.2012.11.003","article-title":"1alpha,25-Dihydroxyvitamin D3 reduces several types of UV-induced DNA damage and contributes to photoprotection","volume":"136","author":"Mason","year":"2013","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"36","doi-asserted-by":"crossref","first-page":"e0126394","DOI":"10.1371\/journal.pone.0126394","article-title":"Vitamin D deficiency at melanoma diagnosis is associated with higher Breslow thickness","volume":"10","author":"Kimlin","year":"2015","journal-title":"PloS One"},{"key":"37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1523-1747.ep12371783","article-title":"Ras mutations in human melanoma: a marker of malignant progression","volume":"102","author":"Hoeffler","year":"1994","journal-title":"The Journal of Investigative Dermatology"},{"key":"38","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/MCB.9.7.3114","article-title":"N-ras mutations in human cutaneous melanoma from sun-exposed body sites","volume":"9","author":"Bos","year":"1989","journal-title":"Molecular and Cellular Biology"},{"key":"39","first-page":"883","article-title":"Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma","volume":"149","author":"Schrier","year":"1996","journal-title":"The American Journal of Pathology"},{"key":"40","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","article-title":"BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage","volume":"19","author":"Wolfe","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1039\/B507471A","article-title":"Cellular aspects of photocarcinogenesis","volume":"5","author":"Nishigori","year":"2006","journal-title":"Photochemical & Photobiological Sciences"},{"key":"42","doi-asserted-by":"crossref","first-page":"e7887","DOI":"10.1371\/journal.pone.0007887","article-title":"Profiling critical cancer gene mutations in clinical tumor samples","volume":"4","author":"Baker","year":"2009","journal-title":"PloS One"},{"key":"43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2353\/jmoldx.2009.080094","article-title":"LightCycler technology in molecular diagnostics","volume":"11","author":"Wittwer","year":"2009","journal-title":"The Journal of Molecular Diagnostics"},{"key":"44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jmoldx.2013.05.003","article-title":"Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes","volume":"15","author":"Luthra","year":"2013","journal-title":"The Journal of Molecular Diagnostics"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:53:14Z","timestamp":1589233994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":44,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2106,7,5]]}},"alternative-id":["9351","27191502"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9351","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]}}}